News

⚡Covaxin at Rs 150 Per Dose to Central Govt Not Sustainable in Long Run, Says Bharat Biotech

By PTI

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.

Read Full Story
Read All QuickLY